Form 4: Avenue Therapeutics Interim PFO and COO, David Jin, Reports Acquisition of 65,000 Shares

David Jin, Interim PFO and COO of Avenue Therapeutics, reports the acquisition of 65,000 shares of common stock through restricted stock units.

Summary

• On September 23, 2024, David Jin, the Interim PFO and COO of Avenue Therapeutics, acquired 65,000 shares of common stock.
• These shares were obtained through an award of restricted stock units.
• The restricted stock units will vest in equal installments on September 30, 2024, December 31, 2024, September 23, 2025, and September 23, 2026.
• The shares underlying the restricted stock units will be settled on the earlier of the tenth business day of January following certain terminations of service or a Change in Control event.
• The shares will be distributed in the form of Avenue Therapeutics' common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard regulatory filing indicating insider activity, which can be interpreted as a positive sign of confidence, but it's not inherently indicative of strong positive or negative sentiment.

Positives

• The acquisition of shares by a company officer can be seen as a positive sign, indicating confidence in the company's future.

Future Outlook

The document does not contain specific forward-looking statements, but it outlines the vesting schedule for the restricted stock units.

Industry Context

Form 4 filings are a routine part of the regulatory landscape for publicly traded companies, providing transparency into the transactions of company insiders.

Stakeholder Impact

• The acquisition of shares by a company officer may increase investor confidence.

Key Dates

Keywords

Avenue Therapeutics, David Jin, Form 4, Insider Trading, Restricted Stock Units, ATXI, Beneficial Ownership